Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
Shares of Seres Therapeutics Inc.
rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial of its SER-109 for recurrent C. difficile infections (CDI), or an infection of the colon. Trading volume ballooned to 7.1 million shares, compared with the full-day average of about 876,000 shares. Seres said the study showed that SER-109 resulted in a “highly statistically signifi…